Short Interest in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Drops By 63.6%

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the target of a large drop in short interest in August. As of August 14th, there was short interest totaling 27,000 shares, a drop of 63.6% from the July 30th total of 74,099 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily volume of 50,747 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Friday, July 17th. HC Wainwright assumed coverage on Radiopharm Theranostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $11.00.

Institutional Investors Weigh In On Radiopharm Theranostics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Marex Group plc purchased a new position in Radiopharm Theranostics during the fourth quarter worth $54,000. Virtu Financial LLC acquired a new position in shares of Radiopharm Theranostics in the fourth quarter valued at approximately $76,000. Jane Street Group LLC purchased a new position in shares of Radiopharm Theranostics during the fourth quarter valued at approximately $76,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Radiopharm Theranostics during the fourth quarter valued at approximately $1,007,000.

Radiopharm Theranostics Trading Up 6.6%

Shares of RADX stock traded up $0.15 during mid-day trading on Friday, reaching $2.41. The stock had a trading volume of 333,279 shares, compared to its average volume of 59,357. Radiopharm Theranostics has a 12-month low of $2.04 and a 12-month high of $16.25. The business has a 50-day simple moving average of $3.51 and a 200 day simple moving average of $4.23.

Radiopharm Theranostics (NASDAQ:RADX) last issued its quarterly earnings data on Friday, July 31st. The company reported ($0.81) EPS for the quarter. The company had revenue of $0.49 million for the quarter. On average, analysts forecast that Radiopharm Theranostics will post -2.36 earnings per share for the current fiscal year.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.